ADAM FRIEDMAN: Open Payments
NPI 1588800916 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639,415 in 435 payments from 31 companies in 2025. Trend: 2023 $269,711 · 2024 $382,323 · 2025 $639,415
Speaker / faculty: $305,931Consulting: $271,481Travel & lodging: $42,794Honoraria: $9,300Food & beverage: $8,889Grant: $1,000
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 40 | $130,225 |
| Regeneron Healthcare Solutions, Inc. | 76 | $115,415 |
| Lilly USA, LLC | 39 | $71,845 |
| PFIZER INC. | 33 | $69,661 |
| Galderma Laboratories, L.P. | 27 | $58,459 |
| UCB, Inc. | 46 | $43,285 |
| Novartis Pharmaceuticals Corporation | 25 | $24,438 |
| Janssen Biotech, Inc. | 20 | $22,171 |
| Arcutis Biotherapeutics, Inc. | 14 | $19,932 |
| Incyte Corporation | 30 | $17,285 |
Products named: DUPIXENT, EBGLYSS, CIBINQO, Bimzelx, TREMFYA, Zoryve, SPEVIGO, OPZELURA.
Industry payments across DC — which companies pay providers there.
